Processing

Please wait...

Settings

Settings

Goto Application

1. WO2000034496 - USE OF TRANS-ACTIVATION AND CIS-ACTIVATION TO MODULATE THE PERSISTENCE OF EXPRESSION OF A TRANSGENE

Publication Number WO/2000/034496
Publication Date 15.06.2000
International Application No. PCT/US1999/028637
International Filing Date 03.12.1999
Chapter 2 Demand Filed 16.06.2000
IPC
C07K 14/035 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
03Herpetoviridae, e.g. pseudorabies virus
035Herpes simplex virus I or II
C07K 14/075 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
075Adenoviridae
C12N 15/63 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/861 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
CPC
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
C12N 2710/10322
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10311Mastadenovirus, e.g. human or simian adenoviruses
10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • GENVEC, INC. [US]/[US] (AllExceptUS)
  • BROUGH, Douglas, E. [US]/[US] (UsOnly)
  • KOVESDI, Imre [CA]/[US] (UsOnly)
Inventors
  • BROUGH, Douglas, E.
  • KOVESDI, Imre
Agents
  • LARCHER, Carol
Priority Data
09/205,01404.12.1998US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF TRANS-ACTIVATION AND CIS-ACTIVATION TO MODULATE THE PERSISTENCE OF EXPRESSION OF A TRANSGENE
(FR) UTILISATION DE TRANS-ACTIVATION ET DE CIS-ACTIVATION POUR MODULER LA PERSISTANCE DE L'EXPRESSION D'UN TRANSGENE
Abstract
(EN)
Provided are methods of modulating the persistence of the expression in a cell of a transgene, such as a transgene in a non-$i(Herpes) vector or in at least E4$g(D) adenoviral vector, and related systems. One method comprises contacting the cell with a non-$i(Herpes) vector comprising and expressing a gene encoding HSV ICP0, whereupon expression of HSV ICP0 the persistence of expression of the transgene is modulated. Further provided is a system for modulating the persistence of expression of a transgene, which system comprises a non-$i(Herpes) vector comprising (i) a gene encoding HSV ICP0 and (ii) a transgene, wherein the HSV ICP0 modulates the persistence of expression of the transgene and either the non-$i(Herpes) vector comprises the transgene or the system further comprises a vector, in which case the vector comprises the transgene. Another method comprises contacting the cell with an at least E4$g(D) adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, wherein the trans-acting factor modulates the persistence of expression of the transgene and the gene encoding the trans-acting factor is not from the E4 region of an adenovirus. Yet another method comprises contacting a cell simultaneously or sequentially with (i) an at least E4$g(D) adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. Also provided is a system for modulating the persistence of expression of a transgene in an at least E4$g(D) adenoviral vector, which system comprises (i) an at least E4$g(D) adenoviral vector comprising a transgene and (ii) a gene encoding a trans-acting factor, wherein the gene encoding the trans-acting factor is not from the E4 region of an adenovirus, the trans-acting factor modulates the persistence of expression of the transgene, and either the at least E4$g(D) adenoviral vector comprises the gene encoding the trans-acting factor or the system comprises a viral vector, in which case the viral vector comprises the gene encoding the trans-acting factor.
(FR)
L'invention concerne des méthodes de modulation de la persistance de l'expression d'un transgène dans une cellule, tel qu'un transgène dans un vecteur non $i(Herpès) ou dans un vecteur adénoviral au moins E4$g(D), ainsi que des systèmes afférents. Une méthode consiste à mettre en contact la cellule avec un vecteur non $i(Herpès) comprenant et exprimant un gène codant HSV ICP0, l'expression de HSV ICP0 entraînant la modulation de la persistance de l'expression du transgène. L'invention concerne également un système de modulation de la persistance de l'expression d'un transgène, ce système comprenant un vecteur non $i(Herpès) comportant (i) un gène codant HSV ICP0 et (ii) un transgène, HSV ICP0 modulant la persistance de l'expression du transgène et soit le vecteur non $i(Herpès) comprenant le transgène, soit le système comprenant aussi un vecteur auquel cas le vecteur comprend le transgène. Une autre méthode consiste à mettre en contact la cellule avec un vecteur adénoviral au moins E4$g(D) comportant (i) un transgène et (ii) un gène codant un facteur trans-activateur, le facteur trans-activateur modulant la persistance de l'expression du transgène et le gène codant le facteur trans-activateur ne provenant pas de la région E4 d'un adénovirus. Une autre méthode encore consiste à mettre en contact une cellule simultanément ou de manière séquentielle (i) avec un vecteur adénoviral au moins E4$g(D) comprenant un transgène et (ii) avec un vecteur viral comprenant un gène codant un facteur trans-activateur ne provenant pas de la région E4 d'un adénovirus et modulant la persistance de l'expression du transgène. L'invention concerne également un système de modulation de la persistance de l'expression d'un transgène dans un vecteur adénoviral au moins E4$g(D), le système comprenant (i) un vecteur adénoviral au moins E4$g(D) comprenant un transgène et (ii) un gène codant un facteur trans-activateur, le gène codant le facteur trans-activateur ne provenant pas de la région E4 d'un adénovirus, le facteur trans-activateur modulant la persistance de l'expression du transgène et soit le vecteur adénoviral au moins E4$g(D) comprenant le gène codant le facteur trans-activateur, soit le système comprenant un vecteur viral auquel cas le vecteur viral comprend le gène codant le facteur trans-activateur.
Latest bibliographic data on file with the International Bureau